| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
|
Nat Med
|
2002
|
7.06
|
|
2
|
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model.
|
Histochem Cell Biol
|
2008
|
2.39
|
|
3
|
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice.
|
Gut
|
2011
|
1.84
|
|
4
|
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis.
|
J Immunol
|
2007
|
1.69
|
|
5
|
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.
|
Transplantation
|
2004
|
1.68
|
|
6
|
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model.
|
Transplantation
|
2006
|
1.64
|
|
7
|
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis.
|
Gastroenterology
|
2008
|
1.51
|
|
8
|
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
|
J Gastroenterol Hepatol
|
2010
|
1.42
|
|
9
|
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.
|
Transplantation
|
2004
|
1.40
|
|
10
|
Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
|
Clin Cancer Res
|
2007
|
1.30
|
|
11
|
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
|
Int J Cancer
|
2007
|
1.30
|
|
12
|
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
|
Mol Cancer Ther
|
2007
|
1.29
|
|
13
|
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study.
|
Transplant Res
|
2013
|
1.27
|
|
14
|
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
|
Mol Cancer Ther
|
2011
|
1.26
|
|
15
|
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.
|
Cancer Res
|
2008
|
1.26
|
|
16
|
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients.
|
J Immunol
|
2011
|
1.25
|
|
17
|
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages.
|
J Clin Invest
|
2011
|
1.25
|
|
18
|
A cell-based approach to the minimization of immunosuppression in renal transplantation.
|
Transpl Int
|
2008
|
1.24
|
|
19
|
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice.
|
Clin Exp Metastasis
|
2003
|
1.19
|
|
20
|
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.
|
Blood
|
2005
|
1.17
|
|
21
|
Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation.
|
Transpl Int
|
2008
|
1.17
|
|
22
|
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.
|
Transplantation
|
2009
|
1.16
|
|
23
|
IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients.
|
Mol Ther
|
2012
|
1.14
|
|
24
|
Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation.
|
BMC Gastroenterol
|
2012
|
1.13
|
|
25
|
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.
|
BMC Cancer
|
2010
|
1.12
|
|
26
|
Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer.
|
Transpl Int
|
2005
|
1.11
|
|
27
|
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice.
|
J Immunol
|
2008
|
1.10
|
|
28
|
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
|
Eur J Cancer
|
2008
|
1.10
|
|
29
|
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.
|
J Am Soc Nephrol
|
2012
|
1.10
|
|
30
|
Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies.
|
Clin Exp Metastasis
|
2009
|
1.08
|
|
31
|
Interleukin-33 prolongs allograft survival during chronic cardiac rejection.
|
Transpl Int
|
2011
|
1.07
|
|
32
|
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
|
BMC Cancer
|
2010
|
1.06
|
|
33
|
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.
|
Clin Cancer Res
|
2004
|
1.02
|
|
34
|
Mesenchymal stem cells can affect solid organ allograft survival.
|
Transplantation
|
2009
|
1.01
|
|
35
|
Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.
|
Clin Cancer Res
|
2004
|
1.01
|
|
36
|
Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells.
|
Int J Oncol
|
2005
|
0.99
|
|
37
|
Procedures for ethical review for clinical trials within the EU.
|
BMJ
|
2009
|
0.99
|
|
38
|
Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis.
|
Int J Colorectal Dis
|
2005
|
0.97
|
|
39
|
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).
|
J Transl Med
|
2011
|
0.97
|
|
40
|
Mesenchymal stem cells as immunomodulators after liver transplantation.
|
Liver Transpl
|
2009
|
0.97
|
|
41
|
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells.
|
Biochim Biophys Acta
|
2010
|
0.95
|
|
42
|
No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury.
|
Stem Cells
|
2006
|
0.94
|
|
43
|
Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.
|
Hepatology
|
2009
|
0.94
|
|
44
|
ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
|
BMC Cancer
|
2008
|
0.94
|
|
45
|
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
|
Mol Cancer Ther
|
2008
|
0.93
|
|
46
|
Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model.
|
Transpl Immunol
|
2011
|
0.93
|
|
47
|
Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs.
|
Transplant Res
|
2012
|
0.92
|
|
48
|
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
|
Mol Cancer Ther
|
2007
|
0.92
|
|
49
|
Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
|
Anticancer Res
|
2012
|
0.90
|
|
50
|
Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha.
|
Mol Cancer Res
|
2009
|
0.90
|
|
51
|
Caspase 3 inhibition improves survival and reduces early graft injury after ischemia and reperfusion in rat liver transplantation.
|
Transplantation
|
2004
|
0.90
|
|
52
|
Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression.
|
Stem Cells Transl Med
|
2013
|
0.89
|
|
53
|
Toward cell-based therapy of type I diabetes.
|
Trends Immunol
|
2008
|
0.89
|
|
54
|
Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis.
|
Int J Colorectal Dis
|
2005
|
0.88
|
|
55
|
DX5+ NKT cells induce the death of colitis-associated cells: involvement of programmed death ligand-1.
|
Eur J Immunol
|
2006
|
0.88
|
|
56
|
Human regulatory macrophages.
|
Methods Mol Biol
|
2011
|
0.87
|
|
57
|
Human regulatory macrophages as a cell-based medicinal product.
|
Curr Opin Organ Transplant
|
2012
|
0.87
|
|
58
|
Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo.
|
Cancer Biol Ther
|
2007
|
0.86
|
|
59
|
Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
|
Transpl Int
|
2007
|
0.86
|
|
60
|
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
|
Anticancer Drugs
|
2007
|
0.86
|
|
61
|
Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation.
|
Curr Opin Organ Transplant
|
2012
|
0.85
|
|
62
|
KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma.
|
J Immunol
|
2014
|
0.85
|
|
63
|
STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.
|
Neoplasia
|
2012
|
0.85
|
|
64
|
DX5+NKT cells display phenotypical and functional differences between spleen and liver as well as NK1.1-Balb/c and NK1.1+ C57Bl/6 mice.
|
BMC Immunol
|
2011
|
0.84
|
|
65
|
Unconventional RORγt+ T cells drive hepatic ischemia reperfusion injury.
|
J Immunol
|
2013
|
0.84
|
|
66
|
Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence.
|
Transplantation
|
2011
|
0.83
|
|
67
|
Mouse β-defensin 14 (Defb14) promotes tumor growth by inducing angiogenesis in a CCR6-dependent manner.
|
J Immunol
|
2012
|
0.83
|
|
68
|
Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation.
|
Trials
|
2012
|
0.83
|
|
69
|
Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models.
|
Surgery
|
2009
|
0.83
|
|
70
|
Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability.
|
Transplantation
|
2007
|
0.82
|
|
71
|
Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.
|
Exp Hematol
|
2007
|
0.81
|
|
72
|
Single cell tracking of gadolinium labeled CD4+ T cells by laser ablation inductively coupled plasma mass spectrometry.
|
Anal Chem
|
2013
|
0.80
|
|
73
|
Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible.
|
Clin Transplant
|
2009
|
0.80
|
|
74
|
IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3β.
|
J Immunol
|
2014
|
0.79
|
|
75
|
Human transplant acceptance-inducing cells suppress mitogen-stimulated T cell proliferation.
|
Transpl Immunol
|
2009
|
0.79
|
|
76
|
Clinical management of patients receiving cell-based immunoregulatory therapy.
|
Transfusion
|
2014
|
0.79
|
|
77
|
Improved outcome after 'bottom-up' immunosuppression in liver transplant recipients with preoperative renal impairment.
|
Eur Surg Res
|
2010
|
0.79
|
|
78
|
Dietary immunosuppressants do not enhance UV-induced skin carcinogenesis, and reveal discordance between p53-mutant early clones and carcinomas.
|
Cancer Prev Res (Phila)
|
2012
|
0.79
|
|
79
|
The antineoplastic drug Paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model.
|
Transplantation
|
2002
|
0.78
|
|
80
|
IL-13 signaling via IL-13Rα2 triggers TGF-β1-dependent allograft fibrosis.
|
Transplant Res
|
2013
|
0.78
|
|
81
|
No acceleration of UV-induced skin carcinogenesis from evenly spread dietary intake of cyclosporine in contrast to oral bolus dosages.
|
Transplantation
|
2013
|
0.78
|
|
82
|
Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study.
|
BMC Nephrol
|
2010
|
0.78
|
|
83
|
Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells.
|
Transpl Int
|
2008
|
0.78
|
|
84
|
A color-coded reporter model to study the effect of immunosuppressants on CD8+ T-cell memory in antitumor and alloimmune responses.
|
Transplantation
|
2013
|
0.78
|
|
85
|
The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy.
|
Transplant Res
|
2013
|
0.77
|
|
86
|
Migration and chemokine receptor pattern of colitis-preventing DX5+NKT cells.
|
Int J Colorectal Dis
|
2011
|
0.77
|
|
87
|
Double deficiency for RORγt and T-bet drives Th2-mediated allograft rejection in mice.
|
J Immunol
|
2013
|
0.77
|
|
88
|
Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma.
|
Oncol Rep
|
2002
|
0.77
|
|
89
|
Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors.
|
Anticancer Res
|
2012
|
0.77
|
|
90
|
Allogeneic bone marrow transplantation restores liver function in Fah-knockout mice.
|
Exp Hematol
|
2008
|
0.77
|
|
91
|
Distribution of intrahepatic T, NK and CD3(+)CD56(+)NKT cells alters after liver transplantation: Shift from innate to adaptive immunity?
|
Transpl Immunol
|
2011
|
0.77
|
|
92
|
CD27low natural killer cells prolong allograft survival in mice by controlling alloreactive CD8+ T cells in a T-bet-dependent manner.
|
Transplantation
|
2015
|
0.76
|
|
93
|
Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used.
|
Transplantation
|
2006
|
0.76
|
|
94
|
Friend or foe: A novel role of β-defensins in tumor development.
|
Oncoimmunology
|
2012
|
0.76
|
|
95
|
Extended pancreas donor program - the EXPAND study rationale and study protocol.
|
Transplant Res
|
2013
|
0.75
|
|
96
|
AAV plasmid DNA simplifies liver-directed in vivo gene therapy: comparison of expression levels after plasmid DNA-, adeno-associated virus- and adenovirus-mediated liver transfection.
|
J Gene Med
|
2010
|
0.75
|
|
97
|
Use of an adenoviral vector to express soluble donor-major histocompatibility complex molecules capable of suppressing the immune response in rat transplant recipients.
|
Hum Immunol
|
2002
|
0.75
|
|
98
|
Transplantation: can sirolimus prevent skin cancer in transplant recipients?
|
Nat Rev Nephrol
|
2010
|
0.75
|
|
99
|
DHRS9 is a Stable Marker of Human Regulatory Macrophages.
|
Transplantation
|
2017
|
0.75
|
|
100
|
Early Enrichment and Restitution of the Peripheral Blood Treg Pool Is Associated With Rejection-Free Stable Immunosuppression After Liver Transplantation.
|
Transplantation
|
2016
|
0.75
|
|
101
|
Donor-specific anti-HLA Antibodies Present in Pooled Human Serum do not Prevent Development of Human Mreg_UKR from Monocytes in Culture.
|
Transplantation
|
2017
|
0.75
|
|
102
|
Evidence-based medicine in daily surgical decision making: a survey-based comparison between the UK and Germany.
|
Eur Surg Res
|
2014
|
0.75
|
|
103
|
Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
|
Transplantation
|
2015
|
0.75
|
|
104
|
Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer.
|
Transpl Int
|
2003
|
0.75
|
|
105
|
Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation.
|
Transplantation
|
2017
|
0.75
|
|
106
|
Hepatocyte expression of soluble donor MHC class I antigen via gene transfer inhibits multiple aspects of the antidonor immune response in fully sensitized rat transplant recipients.
|
Hum Immunol
|
2002
|
0.75
|
|
107
|
Transplantation Reaches 100th Volume.
|
Transplantation
|
2016
|
0.75
|
|
108
|
Message from the editors.
|
Transplantation
|
2015
|
0.75
|